SCHEMBL1819286

SCHEMBL1819286

CONC(=O)C(C)(Oc1ccc(C)cc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46
KCNN4 O15554 1/20 0.39
KIF11 P52732 5/20 0.39
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
KMT2A Q03164 5/20 0.37
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 4/20 0.37
MEN1 O00255 4/20 0.37
SMN1; SMN2 Q16637 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1818707 0.91 PPARA (0.47) PPARGPPARAKCNN4HDAC3HDAC4
SCHEMBL1820277 0.90 PPARG (0.47) PPARGPPARAKCNN4KIF11KMT2A
SCHEMBL1821690 0.89 PPARG (0.46) PPARGPPARAKCNN4HDAC3HDAC4
SCHEMBL9127546 0.84 KCNN4 (0.50) PPARGPPARAKCNN4KIF11HDAC3
SCHEMBL1820711 0.82 MCL1 (0.43) PPARGPPARAHDAC8KMT2AKDM4E
SCHEMBL1819391 0.81 NPC1 (0.43) PPARGPPARAKMT2AMEN1SMN1; SMN2
SCHEMBL1821618 0.79 PPARA (0.44) PPARGPPARAKCNN4HDAC3HDAC4
SCHEMBL1819151 0.79 CNR1 (0.41) PPARGPPARAKMT2AKDM4EALDH1A1
SCHEMBL1824421 0.77 BCHE (0.47) PPARGPPARAKMT2AKDM4EALDH1A1
SCHEMBL1818640 0.75 HDAC3 (0.58) PPARGPPARAKCNN4HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947712-B2 Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent WYETH LLC (US) 2011-05-24 US disclosed
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof WYETH (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269213-A1 8-Hydroxyquinoline compounds and methods thereof MMP8, MMP26, MMP9 PPARG 1416/4885PPARA 2595/4885KCNN4 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.